{"entity":{"id":"st-1898","kind":"drug","name":"ST-1898","aka":["ACC-1898"],"tldr":"ST-1898 is an experimental small molecule, multi-target tyrosine kinase inhibitor from Beijing Scitech-Mq Pharmaceuticals, in phase 2 trials for unresectable or metastatic melanoma, advanced renal cell carcinoma and radioiodine-refractory differentiated thyroid cancer and other cancers.","summary":"ST-1898 (ACC-1898) is a small molecule (oral tablet), multi-target tyrosine kinase inhibitor from Beijing Scitech-Mq Pharmaceuticals, with AccSalus Biosciences as partner. A receptor tyrosine kinase inhibitor with multiple targets, especially VEGFR2, c-MET, AXL, PDGFRA, RET and KIT. Its furthest stage is phase 2, for unresectable or metastatic melanoma, advanced renal cell carcinoma, radioiodine-refractory differentiated thyroid cancer and hepatocellular carcinoma. ClinicalTrials.gov registers it in 4 studies linked below. Phase 2 RAIR-DTC (NCT06359847) and phase 1b/2 melanoma (NCT06359860) recruiting; phase 1b/2 RCC (NCT06127238) active not recruiting; US phase 1 as ACC-1898 (NCT07252661) not yet recruiting. Whether it works in people has not been established unless a trial below reports it.","status":"phase-2","asOf":"2026-11-03","links":[{"label":"Beijing Scitech-Mq Pharmaceuticals: clinicaltrials.gov","url":"https://clinicaltrials.gov/api/v2/studies/NCT06127238"},{"label":"Beijing Scitech-Mq Pharmaceuticals: clinicaltrials.gov","url":"https://clinicaltrials.gov/api/v2/studies/NCT06359847"},{"label":"Beijing Scitech-Mq Pharmaceuticals: clinicaltrials.gov","url":"https://clinicaltrials.gov/api/v2/studies/NCT07252661"},{"label":"ClinicalTrials.gov: trials of ST-1898","url":"https://clinicaltrials.gov/search?intr=ST-1898"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["melanoma","rcc","thyroid","hcc","medullary-thyroid-cancer","gastric"],"sections":[],"technologies":[],"targets":["met","axl","pdgfra","ret","kit"],"drugs":[],"companies":["beijing-scitech-mq-pharmaceuticals","accsalus-biosciences"],"institutions":[],"pathways":[],"terms":[],"trials":["nct06359860","nct06127238","nct06359847","nct07252661"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo gap audit, class 5 (company pipeline pages and ClinicalTrials.gov v2)","editedOn":"2026-11-03"},"code":"ST-1898","modality":"Small molecule (oral tablet), multi-target tyrosine kinase inhibitor","mechanism":"A receptor tyrosine kinase inhibitor with multiple targets, especially VEGFR2, c-MET, AXL, PDGFRA, RET and KIT.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/st-1898/","neighbours":{"cancer":[{"id":"gastric","kind":"cancer","name":"Gastric & gastro-oesophageal junction cancer","route":"/cancers/gastric/"},{"id":"hcc","kind":"cancer","name":"Hepatocellular carcinoma","route":"/cancers/hcc/"},{"id":"medullary-thyroid-cancer","kind":"cancer","name":"Medullary thyroid cancer","route":"/cancers/medullary-thyroid-cancer/"},{"id":"melanoma","kind":"cancer","name":"Melanoma","route":"/cancers/melanoma/"},{"id":"rcc","kind":"cancer","name":"Renal cell carcinoma","route":"/cancers/rcc/"},{"id":"thyroid","kind":"cancer","name":"Thyroid cancer","route":"/cancers/thyroid/"}],"target":[{"id":"axl","kind":"target","name":"AXL","route":"/targets/axl/"},{"id":"kit","kind":"target","name":"KIT","route":"/targets/kit/"},{"id":"met","kind":"target","name":"MET","route":"/targets/met/"},{"id":"pdgfra","kind":"target","name":"PDGFRA","route":"/targets/pdgfra/"},{"id":"ret","kind":"target","name":"RET","route":"/targets/ret/"}],"company":[{"id":"accsalus-biosciences","kind":"company","name":"AccSalus Biosciences","route":"/companies/accsalus-biosciences/"},{"id":"beijing-scitech-mq-pharmaceuticals","kind":"company","name":"Beijing Scitech-Mq Pharmaceuticals","route":"/companies/beijing-scitech-mq-pharmaceuticals/"}],"trial":[{"id":"nct06359860","kind":"trial","name":"A Study of ST-1898 for Unresectable or Metastatic Melanoma","route":"/trials/nct06359860/"},{"id":"nct07252661","kind":"trial","name":"Study of ACC-1898 in Adult Participants With Advanced Solid Tumors","route":"/trials/nct07252661/"},{"id":"nct06127238","kind":"trial","name":"Study of ST-1898 in Advanced Renal Cell Carcinoma","route":"/trials/nct06127238/"},{"id":"nct06359847","kind":"trial","name":"Study of ST-1898 in Locally Advanced or Metastatic Radioiodine-Refractory Differentiated Thyroid Cancer","route":"/trials/nct06359847/"}]}}